Wockhardt Limited
NSE: WOCKPHARMA · Pharmaceuticals · sector
₹1,809.60NSE close 2026-10-26
Key numbers
Market cap₹29,316 cr
Price₹1,809.60
52w high / low₹2,422 / ₹1,087
P/E71.8xSector median 27.9x
P/B5.9xSector median 2.9x
Book value₹304.9
Dividend yield–Sector median 0.48%
ROE8.8%Sector median 11.7%
ROCE9.6%Sector median 12.3%
OPM22.0%Sector median 14.0%
Debt / equity0.43xSector median 0.16x
EV/EBITDA39.3xSector median 18.6x
Interest cover3.1x
Current ratio1.61x
Sales growth 3y+8.4%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹662 cr vs borrowings ₹2,125 cr (FY26): borrowings are higher by ₹1,463 cr.
- Operating profit covered interest 3.1x in the last 12 months.
- 9.97% of the promoters' shares are pledged (4.9% of all shares).
- Operating cash flow was below net profit in 0 of the last 5 years.
- Net loss in 3 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 30% of net profit in the last 12 months.
- Debtor days went from 81 (FY24) to 64 (FY26).
- No dividend in the last 5 financial years.
- Price ₹1,809.60 on 2026-10-26: -25.3% from the 52-week high, +66.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,287.70 · low ₹957.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 |
| EBITDA | 110 | 128 | 64 | -25 | 178 | 167 | 247 | 192 |
| OPM % | 13.6% | 17.8% | 8.6% | -3.4% | 22.8% | 18.8% | 25.6% | 20.7% |
| Other income | 9 | 8 | 15 | 20 | 21 | 25 | 45 | 31 |
| Net profit | -22 | 14 | -25 | -90 | 78 | 59 | 166 | 106 |
| EPS (₹) | -1.47 | 0.91 | -1.57 | -5.53 | 4.81 | 3.61 | 10.23 | 6.55 |
| Revenue YoY | -3.3% | +23.2% | +29.9% | +25.9% | ||||
| Profit YoY | – | +321.4% | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,564 |
| EBITDA | 115 | -193 | 25 | 393 | 567 | 784 |
| Net profit | -244 | -559 | -463 | -47 | 213 | 409 |
| EPS (₹) | -20.24 | -38.79 | -32.05 | -3.02 | 13.12 | 25.20 |
| Revenue growth | -17.9% | +5.5% | +7.6% | +12.0% | +18.4% | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +8.4% | +4.5% | +18.4% |
| Net profit | – | -20.9% | – |
| EPS | – | -26.7% | – |
| Share price | – | +32.7% (2y) | +36.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 3,354 | 3,359 | 4,353 | 4,940 |
| Borrowings | – | 1,887 | 2,112 | 1,859 | 2,125 |
| Cash & equivalents | – | 124 | 529 | 613 | 662 |
| Total assets | – | 7,683 | 7,649 | 8,135 | 8,615 |
| Fixed assets | – | 2,022 | 1,875 | 1,718 | 1,618 |
| Capital work in progress | – | 414 | 434 | 513 | 671 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 797 | 618 | 661 | 588 |
| Inventory | – | 658 | 640 | 725 | 887 |
| Payables | – | 867 | 766 | 592 | 563 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 413 | 153 | 219 | -22 | 390 |
| Cash from investing | -201 | -125 | -137 | -783 | -241 |
| Cash from financing | -71 | -315 | 334 | 409 | -54 |
| Capex | 212 | 42 | 59 | 365 | 364 |
| Free cash flow | 201 | 111 | 160 | -387 | 26 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -16.7% | -13.8% | -1.1% | 4.3% |
| ROCE % | – | -6.1% | -2.1% | 3.8% | 6.4% |
| Debtor days | – | 110 | 81 | 80 | 64 |
| Inventory days | – | 216 | 201 | 234 | 286 |
| Payable days | – | 285 | 240 | 191 | 182 |
| Cash conversion cycle (days) | – | 41 | 42 | 123 | 168 |
| Working capital days | – | -209 | -94 | 51 | 106 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 49.32% |
| FIIs | 7.02% |
| DIIs | 9.00% |
| of which Mutual funds | 5.99% |
| of which Insurance | 1.86% |
| Government | 0.01% |
| Public (non-institutions) | 34.64% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 49.09% | 49.09% | 49.09% | 49.08% | 49.08% | 49.08% | 49.08% | 49.32% |
| Promoter group | % |
|---|---|
| Themisto Trustee Company Private Limited | 40.39% |
| Pasithee Trustee Company Private Limited | 2.72% |
| Ananke Trustee Company Private Limited | 2.35% |
| Callirhoe Trustee Company Private Limited | 1.92% |
| Callirhoe Trustee Company Private Limited | 0.58% |
| Pasithee Trustee Company Private Limited | 0.40% |
| Habil F Khorakiwala | 0.37% |
| Murtaza Habil Khorakiwala | 0.18% |
| Huzaifa Habil Khorakiwala | 0.17% |
| Ananke Trustee Company Private Limited | 0.17% |
| Themisto Trustee Company Private Limited | 0.08% |
| Nafisa Habil Khorakiwala | 0.00% |
| Miqdad H Khorakiwala | 0.00% |
| Muayyad H Khorakiwala | 0.00% |
| Zahabiya Khorakiwala | 0.00% |
| Public holders above 1% | % |
|---|---|
| Tata Mutual Fund - Tata Small Cap Fund | 2.03% |
| Rekha Jhunjhunwala | 1.75% |
| Sbi Life Insurance Co. Ltd | 1.64% |
| Hsbc Mutual Fund - Hsbc Small Cap Fund | 1.17% |
1,73,116 shareholders. Pledged: 9.97% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| WOCKPHARMA | ₹29,316 cr | 71.8x | 5.9x | 8.8% | 9.6% | 22.0% | +8.4% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-06-21 | Other | Annual General Meeting |
| 2023-08-07 | Other | Annual General Meeting |
| 2022-03-08 | Rights | Rights 3:10@ Premium Rs 220 Per Share |
| 2021-07-23 | Other | Annual General Meeting |
| 2020-07-24 | Other | Annual General Meeting |
| 2019-08-02 | Other | Annual General Meeting |
| 2018-07-25 | Other | Annual General Meeting |
| 2017-07-24 | Other | Annual General Meeting |
| 2016-11-17 | Dividend | Interim Dividend Rs 10/- Per Share (Purose Revised) |
| 2016-08-04 | Other | Annual General Meeting |
| 2015-09-03 | Other | Annual General Meeting |
| 2014-11-13 | Dividend | Interim Dividend - Rs 20/- Per Share |
| 2014-09-04 | Other | Annual General Meeting |
| 2014-02-17 | Dividend | Interim Dividend - Rs 5/- Per Share |
| 2013-11-07 | Dividend | Interim Dividend Rs.5/- Per Share |
| 2013-08-22 | Dividend | Annual General Meeting / Dividend Rs.5 Per Share |
| 2012-09-03 | Other | Annual General Meeting |
| 2011-08-30 | Other | Annual General Meeting |
| 2010-09-08 | Other | Annual General Meeting |
| 2009-06-19 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Chemical and chemical products, pharmaceuticals,medicinal chemical and botanical products
- Trade: Wholesale Trading
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | WOCKPHARMA |
| BSE code | 532300 |
| ISIN | INE049B01025 |
| Face value | ₹5.0 |
| Incorporated | 1999-07-08 |
| Website | www.wockhardt.com |
| Plants (India / abroad) | 8 / 4 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.